Pls move up
gagajing
Posts
-
-
Bought 2800 shares
-
I am not worried at all
-
Today will fly! I will buy another 4000 shares when it’s opening. Already have 8000shares🤟🤟🤟🤟🤟
-
$ARDS Omicron continues to disrupt travel plans on Christmas weekend
More than 6,000 flights have been cancelled globally as pilots, employees call in sick after exposure to COVID-19. -
$ARDS Analyst's Opinion
Consensus Rating
Aridis Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/Downside
According to analysts' consensus price target of $15.67, Aridis Pharmaceuticals has a forecasted upside of 493.4% from its current price of $2.64.Amount of Analyst Coverage
Aridis Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. -
I have 8000 shares@3.73
-
Amazing🤩🤩🤩🤩
-
Aridis Pharmaceuticals Inc. (NASDAQ: ARDS)
Another decent gainer of the day is Aridis Pharmaceuticals Inc., which climbed by over 6% at EOD on December 22nd. It’s worth noting that we’ve covered ARDS stock plenty of times in the past few weeks for its sizable rises. This includes a five-day gain of more than 35% despite a YTD drop of around 50%. While its yearly performance is nothing to write home about, many investors are watching ARDS stock right now for its recent bullish turnaround.
The major reason for its gains comes as the biotech penny stock reported positive news surrounding its monoclonal antibody cocktail’s protection against the Omicron variant. Specifically, the treatment known as AR-701, binds to different proteins in the Covid virus, which allows for refusal of entry into the host’s cells. The company also states that the compound could provide high levels of drug concentration for up to one year from the time of treatment.
“Omicron has rendered current COVID-19 vaccines and monoclonal antibodies substantially less effective, and likely future COVID 19 variants will arise that continue this trend. Our laboratory data suggest that AR-701 has the potential to be a future-proof COVID-19 therapy that can protect against SARS-CoV-2, SARS, or MERS pandemics.”
The CEO of Aridis Pharmaceuticals, Vu Truong This is big news, especially considering the major rise in cases in the past few weeks. So whether this makes ARDS stock worth buying or not is up to you.
-
It’s the best time in. It will Take off when opening
-
long term holding
-
50% Increase today
-
-
She is coming
-
Aridis Pharmaceuticals Inc. (NASDAQ: ARDS)
Another decent gainer of the day is Aridis Pharmaceuticals Inc., which climbed by over 6% at EOD on December 22nd. It’s worth noting that we’ve covered ARDS stock plenty of times in the past few weeks for its sizable rises. This includes a five-day gain of more than 35% despite a YTD drop of around 50%. While its yearly performance is nothing to write home about, many investors are watching ARDS stock right now for its recent bullish turnaround.
The major reason for its gains comes as the biotech penny stock reported positive news surrounding its monoclonal antibody cocktail’s protection against the Omicron variant. Specifically, the treatment known as AR-701, binds to different proteins in the Covid virus, which allows for refusal of entry into the host’s cells. The company also states that the compound could provide high levels of drug concentration for up to one year from the time of treatment.
“Omicron has rendered current COVID-19 vaccines and monoclonal antibodies substantially less effective, and likely future COVID 19 variants will arise that continue this trend. Our laboratory data suggest that AR-701 has the potential to be a future-proof COVID-19 therapy that can protect against SARS-CoV-2, SARS, or MERS pandemics.”
The CEO of Aridis Pharmaceuticals, Vu Truong
This is big news, especially considering the major rise in cases in the past few weeks. So whether this makes ARDS stock worth buying or not is up to you. -
Strong sense. She will turn green before opening
-
Gogogo up
-
I have 6000 shares @4.1
What should I say?
Better don’t move now. Time will win. -
It going up. Don’t worry
ARDS
ARDS
ARDS
ARDS
ARDS
ARDS
ARDS
ARDS
BFRI
ARDS
BFRI
ARDS
BFRI
BFRI
BFRI
ARDS
BFRI
ARDS
ARDS
BFRI